The historical rank and industry rank for 60 Degrees Pharmaceuticals's Net Margin % or its related term are showing as below:
SXTP'
s Net Margin % Range Over the Past 10 Years
Min: -2772.2 Med: -1019.96 Max: -139.11
Current: -754.78
SXTP's Net Margin % is ranked worse than 75.5% of 947
companies
in the Biotechnology industry
Industry Median: -89.56
vs SXTP: -754.78
60 Degrees Pharmaceuticals (NAS:SXTP) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
60 Degrees Pharmaceuticals Net Margin % Related Terms
60 Degrees Pharmaceuticals Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SXTP vs LSBCF, ACUT, PPCB: Net Margin % Comparison
For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
60 Degrees Pharmaceuticals Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where 60 Degrees Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
60 Degrees Pharmaceuticals (SXTP) has a Net Margin % of -1,289.51% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on 60 Degrees Pharmaceuticals and its competitors. According to the industry distribution chart, 60 Degrees Pharmaceuticals ranks #715 out of 947 companies in the Biotechnology industry, placing it in the top 75.5%.
Is 60 Degrees Pharmaceuticals' Net Margin % too high?
60 Degrees Pharmaceuticals' current Net Margin % is -1,289.51%. Based on the distribution chart, 60 Degrees Pharmaceuticals ranks #715 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, 60 Degrees Pharmaceuticals has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does 60 Degrees Pharmaceuticals' Net Margin % compare to LSBCF and ACUT?
According to the Biotechnology industry distribution chart, 60 Degrees Pharmaceuticals ranks #715 out of 947 companies for Net Margin %. This places 60 Degrees Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on 60 Degrees Pharmaceuticals and its competitors. 60 Degrees Pharmaceuticals's current Net Margin % is -1,289.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 60 Degrees Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals (SXTP) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.07, compared to a current price of $1.69 — trading 18.4% below its estimated fair value. The current Net Margin % is -1,289.51%. 60 Degrees Pharmaceuticals' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For 60 Degrees Pharmaceuticals (SXTP), the current Net Margin % is -1,289.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 60 Degrees Pharmaceuticals (SXTP) Overvalued in 2026?
Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals stock appears to be undervalued.
The current stock price of $1.69 is trading 18.4% below its estimated GF Value™ of $2.07.
GuruFocus considers 60 Degrees Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for SXTP:
Net Margin %: -1,289.51%
GF Value™: $2.07 vs. price of $1.69 (18.4% below fair value)
No single metric tells the full story. See the SXTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
44GF Score
Get the complete analysis for SXTP
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SXTP has been successfully added to your 
